South Korea Biologics Market Report by Source (Microbial, Mammalian, and Others), Product (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense, RNAi and Molecular Therapy, and Others), Disease (Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others), Manufacturing (Outsourced, In-House), and Region 2026-2034

July 2026 | 118 pages | ID: SFCDB17C8DEEEN
IMARC Group

Abstracts

South Korea biologics market size reached USD 7,684.3 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 13,476.8 Million by 2034, exhibiting a growth rate (CAGR) of 6.25% during 2026-2034. The increasing government's substantial investment in biotechnology and life sciences, the rising strategic collaborations with global biopharmaceutical companies, and the emerging trend towards personalized medicine across the globe represent some of the key factors driving the market.

Biologics, a frontier in pharmaceutical development, are complex medicines manufactured from living organisms, including humans, animals, and microorganisms. These products are manufactured using biotechnology, involving processes such as recombinant DNA technology, controlled gene expression, and antibody technologies. They encompass a diverse range of product types, including monoclonal antibodies, vaccines, recombinant proteins, gene therapy, and cell therapy. They offer targeted treatment options for various diseases, particularly those where traditional small-molecule drugs fall short. Additionally, they are particularly prominent in the treatment of chronic diseases, including cancer, rheumatoid arthritis, and diabetes, due to their ability to interact with specific targets in the body. Their specificity and efficacy translate into fewer side effects and better patient outcomes. They are driving innovation in personalized medicine, offering treatments tailored to individual patients' needs.

SOUTH KOREA BIOLOGICS MARKET TRENDS:

The biologics market in South Korea is majorly driven by the government's substantial investment in biotechnology and life sciences. This vision aims to bolster South Korea's position as a leading biologics hub by fostering research, development, and commercialization of biopharmaceuticals. Along with this, the aging population in South Korea is increasing the demand for advanced therapeutic options, including biologics, to treat chronic and age-related diseases. The country's strong intellectual property laws and regulatory framework provide a conducive environment for innovation and attract foreign investment. In addition, South Korea's advanced technological infrastructure and skilled workforce are critical enablers for the development and manufacturing of biologics. The trend towards personalized medicine is also driving the growth of the biologics market in South Korea. As healthcare moves towards more customized treatment approaches, biologics offer the precision and efficacy required for such therapies. Moreover, South Korea's strategic collaborations with global biopharmaceutical companies are also a significant trend, helping to transfer knowledge and technology, thus enhancing local capabilities in biologics research and manufacturing. Apart from this, the expansion of healthcare expenditure and insurance coverage for biologic treatments by the South Korean government is fueling the market. In confluence with this, the rapid advancement in biotechnology, including gene editing and cell therapy, is significantly supporting the market. This progress is coupled with increasing clinical trials and research activities in biologics, focusing on a wide range of therapeutic areas. Furthermore, South Korea's proactive approach to adapting to emerging technologies and its commitment to nurturing a biotech-friendly ecosystem are pivotal in driving growth and innovation in its biologics market. Some of the other factors driving the market include technological advancements and changing consumer preferences.

SOUTH KOREA BIOLOGICS MARKET SEGMENTATION:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2026-2034. Our report has categorized the market based on source, product, disease, and manufacturing.

Source Insights:

• Microbial
• Mammalian
• Others

The report has provided a detailed breakup and analysis of the market based on the source. This includes microbial, mammalian, and others.

Product Insights:

• Monoclonal Antibodies
• Vaccines
• Recombinant Proteins
• Antisense, RNAi and Molecular Therapy
• Others

A detailed breakup and analysis of the market based on the product have also been provided in the report. This includes monoclonal antibodies, vaccines, recombinant proteins, antisense, RNAi and molecular therapy, and others.

Disease Insights:

• Oncology
• Immunological Disorders
• Cardiovascular Disorders
• Hematological Disorders
• Others

The report has provided a detailed breakup and analysis of the market based on the disease. This includes oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others.

Manufacturing Insights:

• Outsourced
• In-House

A detailed breakup and analysis of the market based on the manufacturing have also been provided in the report. This includes outsourced and in-house.

Regional Insights:

• Seoul Capital Area
• Yeongnam (Southeastern Region)
• Honam (Southwestern Region)
• Hoseo (Central Region)
• Others

The report has also provided a comprehensive analysis of all the major regional markets, which include Seoul Capital Area, Yeongnam (Southeastern Region), Honam (Southwestern Region), Hoseo (Central Region), and Others.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT
How has the South Korea biologics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the South Korea biologics market?
What is the breakup of the South Korea biologics market on the basis of source?
What is the breakup of the South Korea biologics market on the basis of product?
What is the breakup of the South Korea biologics market on the basis of disease?
What is the breakup of the South Korea biologics market on the basis of manufacturing?
What are the various stages in the value chain of the South Korea biologics market?
What are the key driving factors and challenges in the South Korea biologics?
What is the structure of the South Korea biologics market and who are the key players?
What is the degree of competition in the South Korea biologics market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 SOUTH KOREA BIOLOGICS MARKET - INTRODUCTION

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 SOUTH KOREA BIOLOGICS MARKET LANDSCAPE

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (?2026-2034)

6 SOUTH KOREA BIOLOGICS MARKET - BREAKUP BY SOURCE

6.1 Microbial
  6.1.1 Overview
  6.1.2 Historical and Current Market Trends (2020-2025)
  6.1.3 Market Forecast (?2026-2034)
6.2 Mammalian
  6.2.1 Overview
  6.2.2 Historical and Current Market Trends (2020-2025)
  6.2.3 Market Forecast (?2026-2034)
6.3 Others
  6.3.1 Historical and Current Market Trends (2020-2025)
  6.3.2 Market Forecast (?2026-2034)

7 SOUTH KOREA BIOLOGICS MARKET - BREAKUP BY PRODUCT

7.1 Monoclonal Antibodies
  7.1.1 Overview
  7.1.2 Historical and Current Market Trends (2020-2025)
  7.1.3 Market Forecast (?2026-2034)
7.2 Vaccines
  7.2.1 Overview
  7.2.2 Historical and Current Market Trends (2020-2025)
  7.2.3 Market Forecast (?2026-2034)
7.3 Recombinant Proteins
  7.3.1 Overview
  7.3.2 Historical and Current Market Trends (2020-2025)
  7.3.3 Market Forecast (?2026-2034)
7.4 Antisense, RNAi and Molecular Therapy
  7.4.1 Overview
  7.4.2 Historical and Current Market Trends (2020-2025)
  7.4.3 Market Forecast (?2026-2034)
7.5 Others
  7.5.1 Historical and Current Market Trends (2020-2025)
  7.5.2 Market Forecast (?2026-2034)

8 SOUTH KOREA BIOLOGICS MARKET - BREAKUP BY DISEASE

8.1 Oncology
  8.1.1 Overview
  8.1.2 Historical and Current Market Trends (2020-2025)
  8.1.3 Market Forecast (?2026-2034)
8.2 Immunological Disorders
  8.2.1 Overview
  8.2.2 Historical and Current Market Trends (2020-2025)
  8.2.3 Market Forecast (?2026-2034)
8.3 Cardiovascular Disorders
  8.3.1 Overview
  8.3.2 Historical and Current Market Trends (2020-2025)
  8.3.3 Market Forecast (?2026-2034)
8.4 Hematological Disorders
  8.4.1 Overview
  8.4.2 Historical and Current Market Trends (2020-2025)
  8.4.3 Market Forecast (?2026-2034)
8.5 Others
  8.5.1 Historical and Current Market Trends (2020-2025)
  8.5.2 Market Forecast (?2026-2034)

9 SOUTH KOREA BIOLOGICS MARKET - BREAKUP BY MANUFACTURING

9.1 Outsourced
  9.1.1 Overview
  9.1.2 Historical and Current Market Trends (2020-2025)
  9.1.3 Market Forecast (?2026-2034)
9.2 In-House
  9.2.1 Overview
  9.2.2 Historical and Current Market Trends (2020-2025)
  9.2.3 Market Forecast (?2026-2034)

10 SOUTH KOREA BIOLOGICS MARKET – BREAKUP BY REGION

10.1 Seoul Capital Area
  10.1.1 Overview
  10.1.2 Historical and Current Market Trends (2020-2025)
  10.1.3 Market Breakup by Source
  10.1.4 Market Breakup by Product
  10.1.5 Market Breakup by Disease
  10.1.6 Market Breakup by Manufacturing
  10.1.7 Key Players
  10.1.8 Market Forecast (?2026-2034)
10.2 Yeongnam (Southeastern Region)
  10.2.1 Overview
  10.2.2 Historical and Current Market Trends (2020-2025)
  10.2.3 Market Breakup by Source
  10.2.4 Market Breakup by Product
  10.2.5 Market Breakup by Disease
  10.2.6 Market Breakup by Manufacturing
  10.2.7 Key Players
  10.2.8 Market Forecast (?2026-2034)
10.3 Honam (Southwestern Region)
  10.3.1 Overview
  10.3.2 Historical and Current Market Trends (2020-2025)
  10.3.3 Market Breakup by Source
  10.3.4 Market Breakup by Product
  10.3.5 Market Breakup by Disease
  10.3.6 Market Breakup by Manufacturing
  10.3.7 Key Players
  10.3.8 Market Forecast (?2026-2034)
10.4 Hoseo (Central Region)
  10.4.1 Overview
  10.4.2 Historical and Current Market Trends (2020-2025)
  10.4.3 Market Breakup by Source
  10.4.4 Market Breakup by Product
  10.4.5 Market Breakup by Disease
  10.4.6 Market Breakup by Manufacturing
  10.4.7 Key Players
  10.4.8 Market Forecast (?2026-2034)
10.5 Others
  10.5.1 Historical and Current Market Trends (2020-2025)
  10.5.2 Market Forecast (?2026-2034)

11 SOUTH KOREA BIOLOGICS MARKET – COMPETITIVE LANDSCAPE

11.1 Overview
11.2 Market Structure
11.3 Market Player Positioning
11.4 Top Winning Strategies
11.5 Competitive Dashboard
11.6 Company Evaluation Quadrant

12 PROFILES OF KEY PLAYERS

12.1 Company A
  12.1.1 Business Overview
  12.1.2 Product Portfolio
  12.1.3 Business Strategies
  12.1.4 SWOT Analysis
  12.1.5 Major News and Events
12.2 Company B
  12.2.1 Business Overview
  12.2.2 Product Portfolio
  12.2.3 Business Strategies
  12.2.4 SWOT Analysis
  12.2.5 Major News and Events
12.3 Company C
  12.3.1 Business Overview
  12.3.2 Product Portfolio
  12.3.3 Business Strategies
  12.3.4 SWOT Analysis
  12.3.5 Major News and Events
12.4 Company D
  12.4.1 Business Overview
  12.4.2 Product Portfolio
  12.4.3 Business Strategies
  12.4.4 SWOT Analysis
  12.4.5 Major News and Events
12.5 Company E
  12.5.1 Business Overview
  12.5.2 Product Portfolio
  12.5.3 Business Strategies
  12.5.4 SWOT Analysis
  12.5.5 Major News and Events

13 SOUTH KOREA BIOLOGICS MARKET - INDUSTRY ANALYSIS

13.1 Drivers, Restraints, and Opportunities
  13.1.1 Overview
  13.1.2 Drivers
  13.1.3 Restraints
  13.1.4 Opportunities
13.2 Porters Five Forces Analysis
  13.2.1 Overview
  13.2.2 Bargaining Power of Buyers
  13.2.3 Bargaining Power of Suppliers
  13.2.4 Degree of Competition
  13.2.5 Threat of New Entrants
  13.2.6 Threat of Substitutes
13.3 Value Chain Analysis

14 APPENDIX